Compare BHK & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHK | PRME |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 644.2M | 536.4M |
| IPO Year | N/A | 2022 |
| Metric | BHK | PRME |
|---|---|---|
| Price | $9.03 | $3.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.56 |
| AVG Volume (30 Days) | 264.0K | ★ 4.1M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 8.34% | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | N/A | $7.06 |
| Revenue Next Year | N/A | $47.01 |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $8.69 | $2.67 |
| 52 Week High | $10.12 | $6.94 |
| Indicator | BHK | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 54.61 |
| Support Level | $8.87 | $3.73 |
| Resistance Level | $9.05 | $3.82 |
| Average True Range (ATR) | 0.07 | 0.37 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 39.45 | 43.49 |
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing, under normal market conditions, at least 75% of its managed assets in bonds that are investment-grade quality at the time of investment. The trust, under a normal market scenario, will invest in a range of bonds, including corporate bonds, U.S. government and agency securities, and mortgage-related securities.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.